Type Public (Euronext: IPN) Website www.ipsen.com CEO David Meek (18 Jul 2016–) Number of employees 4,900 | Industry Pharmaceutical Headquarters Paris, France Founded 1929 Parent organization Mayroy SA | |
 | ||
Products Targeted therapeutic areas : oncology, endocrinology and neuromuscular disordersPrimary care treatments (mainly in France): gastroenterology, cognitive disorders and cardiovascular Stock price IPN (EPA) € 91.22 +0.79 (+0.87%)14 Mar, 5:35 PM GMT+1 - Disclaimer Subsidiaries Ipsen Biopharmaceuticals, Inc., Ipsen Biopharm Ltd Profiles | ||
Ipsen company profile on euronews oct 28th 2015
Ipsen is a French pharmaceutical company headquartered in Paris, France. It primarily develops and markets medications used in oncology, endocrinology and the treatment of neuromuscular disorders. It is publicly traded on the Euronext Paris as part of the SBF 120 index.
Contents
- Ipsen company profile on euronews oct 28th 2015
- Overview
- Board of directors
- Management team
- Ipsen Foundation
- References
Overview
Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.4 billion in 2015. Ipsen's ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and oncology. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins.
The Beaufour family, which ranks as the 42nd richest family in France, still owns 57% of its shares and 73% of its voting rights, and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors.
The Board of Directors of Ipsen has appointed David Meek as Chief Executive Officer, effective July 18, 2016. On this date, Marc de Garidel will assume the role of non-executive chairman and will continue to serve the Board of Directors through his deep industry expertise. In addition, Marc de Garidel will advise Mayroy, the Ipsen controlling holding company.
In 2015, Ipsen spent close to €200 million—13% of consolidated sales—on research and development.
In February 2015, the company announced it would Canbex Therapeutics $6.8 million upfront upon completion of a Phase IIA study of Canbex’s lead multiple sclerosis compound, VSN16R.
in October 2016, European Commission approves Ipsen’s Cabometyx (Cabozantinib) Tablets for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.
The CABOSUN study, presented at the European Society for Medical Oncology (ESMO) 2016 congress, showed Cabometyx (Cabozantinib) can decrease the rate of disease progression or death by 31% in advanced renal cell carcinoma (RCC).
End 2016, Ipsen's global presence spans 115 countries. US is the number one affiliate with more than 300 people and nearly €158m sales.
Board of directors
The Board of Directors sets the strategic guidelines for Ipsen’s activities and oversees implementation.
Management team
Corporate executives are responsible for managing the Group’s operations and coordinating the Group’s various scientific, legal, financial, commercial and strategic actions.
Ipsen Foundation
In 1983, Ipsen founded the Ipsen Foundation (Fondation Ipsen) with the help of the Fondation de France to track progress in biomedical research. It is headquartered in Boulogne-Billancourt. It has organised 64 colloquia, and it has partnered with the World Health Organisation, the Fondation Nationale de Gérontologie, Harvard University, the Salk Institute for Biological Studies, the Massachusetts General Hospital, and the academic journals Nature and Cell.